New pain drug could cut opioid use after stomach surgery

NCT ID NCT07330063

Not yet recruiting Symptom relief Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new painkiller called anrikefon in 114 people recovering from laparoscopic stomach cancer surgery. The drug aims to control pain with fewer side effects like nausea and drowsiness than standard opioids. Researchers will measure how much extra opioid pain medicine patients need and how well they tolerate the treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anrikefon (Anruikefen)
What this could lead to: If successful, anrikefon could offer a safer way to manage pain after stomach surgery, with fewer side effects like nausea and less need for strong opioids.
What could go wrong: This is a small, early-stage trial (Phase 2) with only 114 participants. The drug is already approved in China for abdominal surgery pain, but results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRECTOMY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRECTOMY

Contacts and locations

Locations

Tianjin Medical University Cancer Institute & Hospital

Tianjin, 不限, 300000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.